EN
Ovarian cancer rarely announces itself early: the first signals — heaviness in the abdomen, bloating, feeling full quickly — are easily put down to anything at all. So by the time the diagnosis is made, a woman often already has an operation or a course of chemotherapy behind her at home, and the main question is a different one: has everything been taken into account, and what happens next. German gynaecological oncology starts exactly there — not with promises but with working the particular tumour out in detail.
How people usually arrive
Ovarian tumours behave differently: some turn out to be benign cysts, others malignant, and they cannot be told apart by eye. Often a woman arrives with a diagnosis already made but with doubts — whether the stage has been correctly determined, whether the full extent of the tumour was seen, whether the approach is right. The reverse also happens: a mass is found by chance on ultrasound and it has to be established whether it is dangerous at all. In both cases the first step in Germany is not treatment but confirming the picture precisely.
How the diagnosis is confirmed
The assessment is built around straightforward methods: transvaginal ultrasound, CT or MRI of the abdomen and pelvis, a blood test for tumour markers (above all CA-125) and, where needed, positron emission tomography (PET), which shows tissue activity and helps see whether the disease has gone beyond the ovary. Only examination of the tissue itself — histology — gives a definitive answer about the nature of the tumour; in ovarian cancer the material is most often obtained during surgery.
The molecular profile of the tumour is studied separately. In ovarian cancer, testing for mutations in the BRCA1 and BRCA2 genes matters particularly: their presence changes the choice of maintenance therapy and also says something about the risks for close female relatives. In effect the assessment answers not only “what is this” but “what should this be treated with in your case”.
Which approaches are used
The basis of treatment in ovarian cancer is a combination of surgery and drug therapy, and the order depends on how far the disease has spread. The surgeon’s task is to remove as much of the tumour as possible; that stage largely determines the plan that follows. Then, as a rule, comes chemotherapy with platinum drugs combined with taxanes — acting on cells that may have remained unseen.
The standard regimen is increasingly supplemented with more targeted agents: drugs that cut off the tumour’s blood supply, and PARP inhibitors, given as maintenance therapy, especially where there are BRCA mutations. What to use and in what order is decided not by one doctor but by a board — gynaecological oncologist, medical oncologist, radiologist and pathologist look at the case together. Treatment follows approved protocols: every step justified and reproducible rather than depending on an individual specialist’s preferences.
When to ask for a second opinion
If surgery or chemotherapy has already begun at home but doubts remain, it makes sense to start with a second opinion. A German specialist studies your images, histology slides and discharge letters and says plainly whether they confirm the diagnosis and agree with the stage and the plan. Sometimes a review of the histology at a reference laboratory changes the diagnosis — and with it the whole approach. Such a step is not frightening but restores a sense of control: it is clear where you stand and what the options are.
This material is for information only and does not replace a consultation with a doctor. Whether treatment is possible, what it will involve and what it will achieve can be determined only after an examination at the clinic in person.